Gradalis to Participate in the Cantor Global Healthcare Conference
DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) — Gradalis, Inc., a privately held, clinical stage biotechnology…
DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) — Gradalis, Inc., a privately held, clinical stage biotechnology…
DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) — Gradalis, Inc., a privately held, clinical stage biotechnology…
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase…
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase…
Financing led by Asteroid Partners with new investor Gideon Strategic Partners and returning investors Johnson…
Financing led by Asteroid Partners with new investor Gideon Strategic Partners and returning investors Johnson…
NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE…
NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE…
Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET ISELIN, N.J.,…
Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET ISELIN, N.J.,…
SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a…
SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a…
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor…
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor…
The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b…
The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b…
ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b…
–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b…